Colchicine inhibits cellular transport and mitosis by binding to tubulin and preventing its polymerisation as part of the cytoskeleton transport system.1 Although the precise mechanism is unclear, colchicine has an inhibitory action on the NLRP3 inflammasome.1 Inflammasomes are activated in COVID-19 and the degree of activation is correlated with disease severity.2 Colchicine is therefore an attractive candidate to test the role of the inflammasome in COVID-19.3 The gene discussed is NLRP3; the disease is COVID-19.